Home » News

[Submit your news]

  • Nottinghamshire Leukaemia Appeal funded research published 15/1/2018

    Work supported in part by a grant from the NLA has been published in the January 2018 edition of PLoS One. The project adopted a new technique called ‘BH3 profiling’ and showed that it can predict drug combinations that will effectively kill leukaemia cells.

  • NLA coffee morning success 23/10/2017

    The first NLA Coffee Morning was held on the ground floor of the Clinical Haematology Building at City Hospital on Wednesday 18th October.

    The event was organised to offer refreshments to haematology patients and their family and to promote the charity and its work. This will be a regularly occurrence so if you see us please do pop over for a tea or coffee and learn about our charity!

  • Wollaton WI Fundraising Success 12/5/2017

    Wollaton Womens Institute have raised the amazing total of £2004.24 after choosing the Nottinghamshire Leukaemia Appeal as their annual charity.

    The money was raised by a variety of events including a Spring Fayre and Open Nights.

    The cheque was presented by President Eileen Kearsley to Claire Seedhouse.

  • Nottingham University Hospitals research boosted by Nottinghamshire Leukaemia Appeal grant 06/4/2017

    Most patients with Acute Myeloid Leukaemia are treated with chemotherapy but this is successful only in a minority of cases. A plethora of novel agents are available but it is not known which drug will be best for which patient. The NUH haematology research team are seeking to develop same-day tests (called ‘dynamic profiling’) that will predict how a patient will respond to a specific drug. The NLA have contributed a grant of £5500 to this work which is aimed at giving the clinicians valuable information in the move towards personalised therapy.

  • Blood, Sweat and Cures 05/1/2017

    Mike and Lucy Wright with David and Karine Thornhill organised a 2-day sponsored walk in the Derbyshire Dales in September to raise funds for the Nottinghamshire Leukaemia Appeal. David has been treated for Leukaemia and Lucy, his sister is his stem cell donor.

    The 12 mile route on day 1 went from Great Longstone to Birchover via Chatsworth, whilst Day 2  covered 11 miles back to Great Longstone via Lathkill Dale. Walkers were invited to walk for one day or both and a Pie and Peas supper was held on the Saturday evening at ‘The Crispin’.

    As can be seen from the photos a good, and sunny, time was had by all!

    The organisers presented the money raised by the walk, an amazing £1670, to Prof John Fletcher from the NLA in December.

    David Thornhill presenting the cheque to John, watched by Karine Thornhill, BMT nurses Mel and Julie and Mike and Lucy Wright


  • Leukaemia Golf Day 21/11/2016

    This Summer’s Golf Day at Ruddington Grange Gold Club raised a fantastic £11500! Thank you to all organisers and participants!

  • Great Gate Gardens Open Day 07/11/2016

    The Great Gate Gardens Open Day raised an amazing £804!! Thank you very much too all organisers, helpers and bakers and also to all who attended.

  • Drug combination study published 05/10/2016

    Dr Pallis’s research group have recently published Nottinghamshire Leukaemia Appeal funded work in the journal Oncotarget. The work used a method called BH3-profiling to show that a novel drug combination causes significantly more leukaemia cell death than either of the drugs alone. Both of these drugs are currently in clinical trials.

  • Bramcote Sponsored Walk Success 29/9/2016

    The Bramcote sponsored walk earlier this Summer raised more than £2500 for the Appeal!! Well done and many thanks to all walkers and organisers!

  • Work funded by Nottinghamshire Leukaemia Appeal 23/9/2016

    Nottinghamshire Leukaemia Appeal has provided funds of £6600 to further work on a research project being carried out at the University of Nottingham. Whilst many cancer cells grow and divide quickly, a subset remain dormant or ‘sleeping’. Chemotherapy drugs tend not to work on these sleeping cells and this project plans to establish why these cells are resistant to drugs and whether there are specific abnormalities in these cells that may be exploited in future treatment regimens.